SCM
IMRX icon

Suvretta Capital Management’s Immuneering IMRX Stock Holding History

Suvretta Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200,000
Closed -$1.08M – 81
2022
Q2 		$1.08M Hold
200,000
– – 0.04% 83
2022
Q1 		$1.29M Hold
200,000
– – 0.04% 77
2021
Q4 		$3.23M Hold
200,000
– – 0.06% 77
2021
Q3 		$5.31M Buy
+200,000
New +$5.37M 0.09% 77

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Suvretta Capital Management's IMRX Position: Q3 2022 in Review

Suvretta Capital Management sold out of Immuneering (IMRX) in Q3 2022, closing a stake of 200,000 shares — an estimated $1.08M sold.

Suvretta Capital Management first reported a position in IMRX in Q3 2021 and held it in 4 quarters. The position peaked at $5.31M in Q3 2021. 32 funds tracked by Wall St. Rank hold IMRX as of Q3 2022.

  • Suvretta Capital Management reported no remaining Immuneering position as of Q3 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 200,000 Immuneering shares in Q3 2022, an estimated $1.08M.
  • Suvretta Capital Management first reported a position in Immuneering in Q3 2021 and held it in 4 quarters.
  • Suvretta Capital Management's Immuneering position peaked at $5.31M in Q3 2021.
  • 32 funds tracked by Wall St. Rank held Immuneering as of Q3 2022.

Based on Suvretta Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.